Optimizing use of β-lactam antibiotics in the critically ill

Seminars in Respiratory and Critical Care Medicine

Volumn 28, Issue 6, 2007, Pages 579-585

  Roberts, Jason A ^a,b   Lipman, Jeffrey ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

lactam; Antibiotics; Continuous infusion; Critically ill; Resistance

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; INFUSION FLUID; INOTROPIC AGENT; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; HUMAN; INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMS; CRITICAL ILLNESS; HUMANS; INFUSION PUMPS; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME;

EID: 37649001115     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996404     Document Type: Review

References (68)

1. Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 2001;29:S99-S106
2. Rice TW, Bernard GR. Therapeutic intervention and targets for sepsis. Annu Rev Med 2005;56:225-248
3. Roberts JA, Lipman J. Antibiotic dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006;45:755-773
4. Garnacho-Montero J, Garnacho-Montero C, Cayuela A, Ortiz-Leyba C. Timing of adequate antibiotic therapy is more determinant of outcome than TNF and IL-10 polymorphisms in septic patients. Crit Care 2006;10:R111
5. Talbot GH, Bradley J, Edwards JE Jr., Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006;42:657-668
6. Roberts JA, Boots R, Rickard CM, et al. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 2007;59:285-291
7. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997;24:796-809
8. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997;24:786-795
9. Wysocki M, Delatour F, Faurisson F. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001;45:2460-2467
10. Olofsson SK, Marcusson LL, Komp Lindgren P, et al. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother 2006;57:1116-1121
11. Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005;49:4920-4927
12. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998;42:521-527
13. Roosendaal R, Bakker-Woudenberg IA, Van den Berghe JC, van Raafe M, Michel MF. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob Agents Chemother 1986;30:403-408
14. Olofsson SK, Geli P, Andersson DI, Cars O. Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli. Antimicrob Agents Chemother 2005;49:5081-5091
15. Gugel J, Dos Santos Pereira A, Pignatari AC, Gales AC. Beta-Lactam MICs correlate poorly with mutant prevention concentrations for clinical isolates of Acinetobacter spp. and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006;50:2276-2277
16. Firsov AA, Smirnova MV, Lubenko IY, Vostrov SN, Portnoy YA, Zinner SH. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother 2006;58:1185-1192
17. Tsuji B, Rybak M. The influence of Staphylococcus aureus accessory gene regulator function on the development of glycopeptide hetero-resistance in an in vitro pharmacodynamic model. moxifloxacin. In: 15th European Congress on Clinical Microbiology and Infectious Diseases Copenhagen: Blackwell Publishing; 2005:P-1590
18. Craig W. Pharmacokinetic and experimental data on beta-lactam antibiotics in the treatment of patients. Eur J Clin Microbiol 1984;3:575-578
19. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10; quiz 11-12
20. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003;17:479-501
21. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998;27:10-22
22. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of "bug and drug." Nat Rev Microbiol 2004;2:289-300
23. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986;108:835-840
24. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988;158:831-847
25. Vogelman BS, Craig WA. Postantibiotic effects. J Antimicrob Chemother 1985;15(Suppl A):37-46
26. Bakker-Woudenberg IA, Roosendaal R. Impact of dosage schedule of antibiotics on the treatment of serious infections. Intensive Care Med 1990;16(Suppl 3):S229-S234
27. Leggett JE, Fantin B, Ebert S. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989;159:281-292
28. Schentag JJ, Smith IL, Swanson DJ, et al. Role for dual individualization with cefmenoxime. Am J Med 1984;77:43-50
29. Mouton JW, Vinks AA, Punt NC. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 1997;41:733-738
30. Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994;38:931-936
31. Nuytinck HK, Offermans XJ, Kubat K, Goris JA. Whole-body inflammation in trauma patients: an autopsy study. Arch Surg 1988;123:1519-1524
32. Gosling P, Sanghera K, Dickson G. Generalized vascular permeability and pulmonary function in patients following serious trauma. J Trauma 1994;36:477-481
33. Joukhadar C, Frossard M, Mayer BX, et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001;29:385-391
34. Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990;113:227-242
35. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993;328:1471-1477
36. Pea F, Porreca L, Baraldo M, Furlanut M. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000;45:329-335
37. Di Giantomasso D, May CN, Bellomo R. Norepinephrine and vital organ blood flow. Intensive Care Med 2002;28:1804-1809
38. Di Giantomasso D, May CN, Bellomo R. Norepinephrine and vital organ blood flow during experimental hyperdynamic sepsis. Intensive Care Med 2003;29:1774-81
39. Di Giantomasso D, Bellomo R, May CN. The haemodynamic and metabolic effects of epinephrine in experimental hyperdynamic septic shock. Intensive Care Med 2005;31:454-462
40. Livornese LL, Slavin D, Benz RL, Ingerman MJ, Santoro J. Use of antibacterial agents in renal failure. Infect Dis Clin North Am 2001;15:983-1002
41. Livornese LL, Slavin D, Gilbert B, Robbins P, Santoro J. Use of antibacterial agents in renal failure. Infect Dis Clin North Am 2004;18:551-579
42. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005;41:1159-1166
43. Roberts JA, Paratz JD, Paratz E, Krueger WA, Lipman J. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents 2007;30:11-18
44. Lipman J, Wallis SC, Rickard CM, Fraenkel D. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med 2001;27:363-370
45. Lipman J, Wallis SC, Rickard C. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999;43:2559-2561
46. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007;44:357-363
47. Roos JF, Bulitta J, Lipman J, Kirkpatrick CM. Pharmacokinetic- pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother 2006;58:987-993
48. Benko AS, Cappelletty DM, Kruse JA, Rybak MJ. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother 1996;40:691-695
49. Buijk SL, Gyssens IC, Mouton JW, Van Vliet A, Verbrugh HA, Bruining HA. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother 2002;49:121-128
50. Hanes SD, Wood GC, Herring V, et al. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000;179:436-440
51. Roberts JA, Roberts MS, Dalley A, Cross SE, Lipman J. Exposure and predicted antimicrobial efficacy in critically ill patients: piperacillin. Paper presented at: Queensland Branch Conference, Society of Hospital Pharmacists of Australia; October 20-22, 2006; Brisbane, Australia
52. Jaruratanasirikul S, Sriwiriyajan S, Ingviya N. Continuous infusion versus intermittent administration of cefepime in patients with gram-negative bacilli bacteraemia. J Pharm Pharmacol 2002;54:1693-1696
53. Lipman J, Gomersall CD, Gin T, Joynt GM, Young RJ. Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemother 1999;43:309-311
54. Young RJ, Lipman J, Gin T, Gomersall CD, Joynt GM, Oh TE. Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother 1997;40:269-273
55. Boselli E, Breilh D, Rimmele T, et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004;30:989-991
56. Alou L, Aguilar L, Sevillano D, et al. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model. J Antimicrob Chemother 2005;55:209-213
57. Mariat C, Venet C, Jehl F, et al. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltrafion: pharmacokinetic evaluation and dose recommendation. Crit Care 2006;10:R26
58. Rafati MR, Rouini MR, Mojtahedzadeh M, et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 2006;28:122-127
59. Tam VH, Louie A, Lomaestro BM, Drusano GL. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy 2003;23:291-295
60. Georges B, Conil JM, Cougot P, et al. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. Int J Clin Pharmacol Ther 2005;43:360-369
61. Angus BJ, Smith MD, Suputtamongkol Y, et al. Pharmacokinetic- pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol 2000;50:184-191
62. Lau WK, Mercer D, Itani KM, et al. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 2006;50:3556-3561
63. Lorente L, Lorenzo L, Martin MM, Jimenez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006;40:219-223
64. McNabb JJ, Nightingale CH, Quintiliani R, Nicolau DP. Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy 2001;21:549-555
65. Buijs J, Dofferhoff ASM, Mouton JW, van der Meer JWM. Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis. J Antimicrob Chemother 2007;59:926-933
66. Wiedemann B. An international perspective on antimicrobial resistance. Am J Med 1995;99:19S-20S
67. Fantin B, Ebert S, Leggett J, Vogelman B, Craig WA. Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli. J Antimicrob Chemother 1991;27:829-836
68. Odenholt I, Gustafsson I, Lowdin E, Cars O. Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic model. Antimicrob Agents Chemother 2003;47:518-523